125 results on '"Ballatore, Z."'
Search Results
2. Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD)
3. 236P Trastuzumab deruxtecan in Italian real-world experience: Updated analysis from DE-REAL study
4. 209P Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)
5. 224P Clinical features and outcomes in HER2+ mBC patients treated with trastuzumab deruxtecan: A subgroup analysis of the De-REAL study
6. MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)
7. C44 - Role of inflammation parameters in locally advanced breast cancer: the debate is still open
8. C35 - Pathogenetic mutations in BRCA related triple negative breast cancer
9. C23 - Stromal peritumoral and intratumoral infiltrating lymphocytes: how immunity influences prognosis in triple negative breast cancer
10. C7 - Evaluation of stromal tumour-infiltrating lymphocytes (TILs) in breast cancer by Dynamic contrast–enhanced magnetic resonance (DCE-MR) imaging
11. C12 - BRCA related breast cancer and sporadic tumors: same prognosis or survivorship bias?
12. LBA98 Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial
13. 1757P Training and information during COVID-19 pandemic: The masterpiece in young oncologists
14. 1699P COVID-19 pandemic: Patients’ perspective during cancer treatment
15. 1684P Scientia Potentia Est: How the Italian world of oncology changes in the COVID-19 pandemic
16. A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial
17. Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
18. Aromatase Inhibitors in Premenopausal Women with Breast Cancer: The State of the Art and Future Prospects
19. Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex
20. Breast cancer secondary prevention: get fit to feel healthy
21. Stromal peritumoral and intratumoral infiltrating lymphocytes: how immunity influences prognosis in triple negative breast cancer
22. Role of inflammation parameters in locally advanced breast cancer: the debate is still open
23. BRCA related breast cancer and sporadic tumors: same prognosis or survivorship bias?
24. Pathogenetic mutations in BRCA related triple negative breast cancer
25. Prognostic impact of CA15-3 pre-treatment levels in ovarian cancer patients
26. Evaluation of stromal tumour-infiltrating lymphocytes (TILs) in breast cancer by Dynamic contrast–enhanced magnetic resonance (DCE-MR) imaging
27. 335P - Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
28. Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
29. BRCA mutations and IGF-R1 expression in modulating sensitivity to trastuzumab in HER2-positive breast cancer
30. Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer (OC) patients: a single centre experience
31. Triple-negative breast cancer and BRCA mutation: looking at the future
32. Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer patients: a single Centre experience
33. Potential role of PLR and NLR in clinical decision making in locally advanced breast cancer
34. BRCA mutations and IGF-R1 expression in modulating sensitivity to Trastuzumab in patients with HER2-positive breast cancer
35. The link between obesity and advanced breast cancer is a matter of much interest
36. Impact of hormonal receptor status on prognosis in HER2 positive breast cancer
37. Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer
38. Endocrine therapy is not effective in BRCA2 mutated breast cancers even when they express hormonal receptors
39. BRCA1/2 mutations and hereditary breast cancer: clinical phenotype, type of mutation and founder effect
40. Soft tissue sarcoma after haematological malignancies in childhood/adolescence: a hospital series
41. Everolimus in ER + /HER-2 negative metastatic breast cancer (MBC): what we have learned from two years of clinical practice. A single Institution experience
42. Evaluation of clinical and pathological features in patients with Lynch Syndrome-related Endometrial Cancer: a single centre experience
43. Clinical and pathological predictors of outcome for malignant pleural mesothelioma
44. Secondary breast cancer prevention: it's time to get moving!
45. P8 - Breast cancer secondary prevention: get fit to feel healthy
46. H8 - Prognostic impact of CA15-3 pre-treatment levels in ovarian cancer patients
47. PR20 Biology of BRCA-related triple-negative breast cancer: which is the difference with the others?
48. Prognosis of Brca1 and Brca2-Related Breast Cancers: are There Differences?
49. Baseline Neutrophil to Lymphocyte Ratio Correlates with Tumor Stage in Locally Advanced Breast Cancer Patients
50. 865P - Hypersensitivity reactions to antineoplastic agents in BRCA-mutated ovarian cancer (OC) patients: a single centre experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.